Latest period
$64.45B
YoY change
+0.6%
5Y CAGR
+12.0%
Peak year (2023)
$70.84B
Latest annual
$67.42B
Total Debt history chart for Pfizer (PFE) from 1985 to 2025
Latest: $67.42B
Total Debt growth chart for Pfizer (PFE) from 1985 to 2025
Latest: +0.6%
Total Debt history table for Pfizer (PFE) from 1985 to 2025
| 2025 | $67.42B | +0.6% | +$423.00M | ||
| 2024 | $66.99B | -5.4% | −$3.85B | ||
| 2023 | $70.84B | +103.2% | +$35.99B | ||
| 2022 | $34.86B | -5.8% | −$2.14B | ||
| 2021 | $37.00B | -3.3% | −$1.28B | ||
| 2020 | $38.27B | -24.7% | −$12.57B | ||
| 2019 | $50.84B | +21.8% | +$9.10B | ||
| 2018 | $41.74B | -2.0% | −$861.00M | ||
| 2017 | $42.61B | +3.8% | +$1.54B | ||
| 2016 | $41.06B | +5.6% | +$2.16B | ||
| 2015 | $38.90B | +6.0% | +$2.22B | ||
| 2014 | $36.68B | +0.5% | +$193.00M | ||
| 2013 | $36.49B | -2.6% | −$971.00M | ||
| 2012 | $37.46B | -3.8% | −$1.48B | ||
| 2011 | $38.94B | -11.6% | −$5.09B | ||
| 2010 | $44.03B | -9.5% | −$4.63B | ||
| 2009 | $48.66B | +181.6% | +$31.38B | ||
| 2008 | $17.28B | +31.5% | +$4.14B | ||
| 2007 | $13.14B | +64.6% | +$5.16B | ||
| 2006 | $7.98B | -55.5% | −$9.96B | ||
| 2005 | $17.94B | -3.3% | −$609.00M | ||
| 2004 | $18.55B | +27.3% | +$3.97B | ||
| 2003 | $14.57B | +23.4% | +$2.76B | ||
| 2002 | $11.81B | +33.1% | +$2.94B | ||
| 2001 | $8.87B | +63.9% | +$3.46B | ||
| 2000 | $5.41B | -23.5% | −$1.66B | ||
| 1999 | $7.07B | +117.2% | +$3.82B | ||
| 1998 | $3.26B | +9.4% | +$280.00M | ||
| 1997 | $2.98B | +1.8% | +$54.00M | ||
| 1996 | $2.92B | +1.9% | +$53.50M | ||
| 1995 | $2.87B | +1.6% | +$44.30M | ||
| 1994 | $2.82B | +61.4% | +$1.07B | ||
| 1993 | $1.75B | -4.1% | −$74.30M | ||
| 1992 | $1.82B | -12.7% | −$264.10M | ||
| 1991 | $2.09B | +23.3% | +$395.10M | ||
| 1990 | $1.69B | -1.4% | −$24.30M | ||
| 1989 | $1.72B | +43.7% | +$522.30M | ||
| 1988 | $1.19B | +23.9% | +$230.80M | ||
| 1987 | $963.80M | +73.1% | +$407.10M | ||
| 1986 | $556.70M | +9.3% | +$47.30M | ||
| 1985 | $509.40M | — | — |
- 2025$67.42B+0.6%
- 2024$66.99B-5.4%
- 2023$70.84B+103.2%
- 2022$34.86B-5.8%
- 2021$37.00B-3.3%
- 2020$38.27B-24.7%
- 2019$50.84B+21.8%
- 2018$41.74B-2.0%
- 2017$42.61B+3.8%
- 2016$41.06B+5.6%
- 2015$38.90B+6.0%
- 2014$36.68B+0.5%
- 2013$36.49B-2.6%
- 2012$37.46B-3.8%
- 2011$38.94B-11.6%
- 2010$44.03B-9.5%
- 2009$48.66B+181.6%
- 2008$17.28B+31.5%
- 2007$13.14B+64.6%
- 2006$7.98B-55.5%
- 2005$17.94B-3.3%
- 2004$18.55B+27.3%
- 2003$14.57B+23.4%
- 2002$11.81B+33.1%
- 2001$8.87B+63.9%
- 2000$5.41B-23.5%
- 1999$7.07B+117.2%
- 1998$3.26B+9.4%
- 1997$2.98B+1.8%
- 1996$2.92B+1.9%
- 1995$2.87B+1.6%
- 1994$2.82B+61.4%
- 1993$1.75B-4.1%
- 1992$1.82B-12.7%
- 1991$2.09B+23.3%
- 1990$1.69B-1.4%
- 1989$1.72B+43.7%
- 1988$1.19B+23.9%
- 1987$963.80M+73.1%
- 1986$556.70M+9.3%
- 1985$509.40M—
Total Debt values are taken from Pfizer's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Debt at Pfizer (PFE)
According to Pfizer's latest reported financial statements, the company's latest reported total debt is $64.45B. Total debt is the sum of short-term and long-term interest-bearing borrowings on the balance sheet (notes, bonds, term loans, lease liabilities). Useful for leverage and refinancing risk — compare with cash on hand for net leverage, and total liabilities for the broader obligations picture.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Pfizer (PFE) total debt totalled $67.42B – edged up 0.6% year-over-year.
Pfizer total debt compound annual growth for the 2020–2025 (5 years) window is +12.0%, with mixed annual results across the window.
2023 marks the peak total debt at $70.84B, with the historical low of $509.40M recorded in 1985.
Pfizer Total Debt by Year
Pfizer Total Debt 2025: $67.42B
In 2025, Pfizer reported total debt of $67.42B, edged up 0.6% from 2024.
Pfizer Total Debt 2024: $66.99B
Pfizer total debt in 2024 was $66.99B, declined 5.4% below 2023.
Pfizer Total Debt 2023: $70.84B
2023's total debt for Pfizer came in at $70.84B, surged 103.2% from 2022. This figure represents the highest annual value in the available history.
Pfizer Total Debt 2022: $34.86B
Pfizer posted total debt of $34.86B in 2022, declined 5.8% below 2021.
Pfizer Total Debt 2021: $37.00B
Pfizer total debt in 2021 was $37.00B.
See more financial history for Pfizer (PFE).
Sector peers by Total Debt
Healthcare peers of Pfizer (PFE), ranked by their latest total debt
| $78.39B | |
| $69.07B | |
| $54.60B | |
| $50.53B | |
| $47.93B | |
| $42.50B | |
| $29.70B | |
| $20.59B |
- $78.39B
- $69.07B
- $54.60B
- $50.53B
- $47.93B
- $42.50B
- $29.70B
- $20.59B
Frequently asked questions
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation